Amy Sims - Researcher Profile | RDL Research Database

Publications

2 shown

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Timothy P. Sheahan , Amy Sims , Sarah R. Leist +16 more

Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease associated with more than 2468 human infections and over 851 death...

2020 Nature Communications 1785 citations

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Maria L. Agostini , Erica L. Andres , Amy Sims +14 more

ABSTRACT Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved therapeutics are available. The CoV nsp14 exoribonuclease (ExoN) has complicated developme...

2018 mBio 1493 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 3,278
Institution: University of North Carolina at Chapel Hill

External Links

Google Scholar

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.